Defining cancer risk in dermatomyositis. Part II. Assessing diagnostic usefulness of myositis serology

V. Madan; H. Chinoy; C. E M Griffiths; R. G. Cooper

doi:10.1111/j.1365-2230.2009.03227.x

Defining cancer risk in dermatomyositis. Part II. Assessing diagnostic usefulness of myositis serology

V. Madan, H. Chinoy, C. E M Griffiths, R. G. Cooper

Research output: Contribution to journal › Article › peer-review

90 Downloads (Pure)

Abstract

In part 1 of this review, we examined the evidence behind the association between idiopathic inflammatory myopathies (IIM) and cancers. In view of the well-recognized association between cancer and myositis (hence the term cancer-associated myositis, or CAM), clinicians responsible for the management of patients with myositis must make important decisions regarding how intensively they undertake searches for malignancy. Clinicians must also decide how often such searches are repeated, and again how intensively, to optimize both cancer detection and treatment, and thus patient survival. As the risks of CAM are greatest in dermatomyositis, this is an issue of obvious importance to dermatologists. In this second of two reviews, we examine the role of autoantibodies as potential predictors of cancer risk in patients with IIM. © 2009 British Association of Dermatologists.

Original language	English
Pages (from-to)	561-565
Number of pages	4
Journal	Clinical and Experimental Dermatology
Volume	34
Issue number	5
DOIs	https://doi.org/10.1111/j.1365-2230.2009.03227.x
Publication status	Published - Jul 2009

Keywords

IDIOPATHIC INFLAMMATORY MYOPATHIES
CLINICALLY AMYOPATHIC DERMATOMYOSITIS
SIGNAL RECOGNITION PARTICLE
POPULATION-BASED COHORT
RNA-BINDING PROTEIN
ANTI-MI-2 ANTIBODIES
JAPANESE PATIENTS
AUTOANTIBODIES
POLYMYOSITIS
MALIGNANCY

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/j.1365-2230.2009.03227.x

POST-PEER-REVIEW-NON-PUBLISHERS.DOCAccepted author manuscript, 144 KB

Cite this

@article{6ac09ee5805846aa9d2ed4a6e97e5c5e,

title = "Defining cancer risk in dermatomyositis. Part II. Assessing diagnostic usefulness of myositis serology",

abstract = "In part 1 of this review, we examined the evidence behind the association between idiopathic inflammatory myopathies (IIM) and cancers. In view of the well-recognized association between cancer and myositis (hence the term cancer-associated myositis, or CAM), clinicians responsible for the management of patients with myositis must make important decisions regarding how intensively they undertake searches for malignancy. Clinicians must also decide how often such searches are repeated, and again how intensively, to optimize both cancer detection and treatment, and thus patient survival. As the risks of CAM are greatest in dermatomyositis, this is an issue of obvious importance to dermatologists. In this second of two reviews, we examine the role of autoantibodies as potential predictors of cancer risk in patients with IIM. {\textcopyright} 2009 British Association of Dermatologists.",

keywords = "IDIOPATHIC INFLAMMATORY MYOPATHIES, CLINICALLY AMYOPATHIC DERMATOMYOSITIS, SIGNAL RECOGNITION PARTICLE, POPULATION-BASED COHORT, RNA-BINDING PROTEIN, ANTI-MI-2 ANTIBODIES, JAPANESE PATIENTS, AUTOANTIBODIES, POLYMYOSITIS, MALIGNANCY",

author = "V. Madan and H. Chinoy and Griffiths, {C. E M} and Cooper, {R. G.}",

year = "2009",

month = jul,

doi = "10.1111/j.1365-2230.2009.03227.x",

language = "English",

volume = "34",

pages = "561--565",

journal = "Clinical and Experimental Dermatology",

issn = "0307-6938",

publisher = "Oxford University Press",

number = "5",

}

TY - JOUR

T1 - Defining cancer risk in dermatomyositis. Part II. Assessing diagnostic usefulness of myositis serology

AU - Madan, V.

AU - Chinoy, H.

AU - Griffiths, C. E M

AU - Cooper, R. G.

PY - 2009/7

Y1 - 2009/7

N2 - In part 1 of this review, we examined the evidence behind the association between idiopathic inflammatory myopathies (IIM) and cancers. In view of the well-recognized association between cancer and myositis (hence the term cancer-associated myositis, or CAM), clinicians responsible for the management of patients with myositis must make important decisions regarding how intensively they undertake searches for malignancy. Clinicians must also decide how often such searches are repeated, and again how intensively, to optimize both cancer detection and treatment, and thus patient survival. As the risks of CAM are greatest in dermatomyositis, this is an issue of obvious importance to dermatologists. In this second of two reviews, we examine the role of autoantibodies as potential predictors of cancer risk in patients with IIM. © 2009 British Association of Dermatologists.

AB - In part 1 of this review, we examined the evidence behind the association between idiopathic inflammatory myopathies (IIM) and cancers. In view of the well-recognized association between cancer and myositis (hence the term cancer-associated myositis, or CAM), clinicians responsible for the management of patients with myositis must make important decisions regarding how intensively they undertake searches for malignancy. Clinicians must also decide how often such searches are repeated, and again how intensively, to optimize both cancer detection and treatment, and thus patient survival. As the risks of CAM are greatest in dermatomyositis, this is an issue of obvious importance to dermatologists. In this second of two reviews, we examine the role of autoantibodies as potential predictors of cancer risk in patients with IIM. © 2009 British Association of Dermatologists.

KW - IDIOPATHIC INFLAMMATORY MYOPATHIES

KW - CLINICALLY AMYOPATHIC DERMATOMYOSITIS

KW - SIGNAL RECOGNITION PARTICLE

KW - POPULATION-BASED COHORT

KW - RNA-BINDING PROTEIN

KW - ANTI-MI-2 ANTIBODIES

KW - JAPANESE PATIENTS

KW - AUTOANTIBODIES

KW - POLYMYOSITIS

KW - MALIGNANCY

U2 - 10.1111/j.1365-2230.2009.03227.x

DO - 10.1111/j.1365-2230.2009.03227.x

M3 - Article

C2 - 19508476

SN - 0307-6938

VL - 34

SP - 561

EP - 565

JO - Clinical and Experimental Dermatology

JF - Clinical and Experimental Dermatology

IS - 5

ER -

Defining cancer risk in dermatomyositis. Part II. Assessing diagnostic usefulness of myositis serology

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this